1. Home
  2. IVA vs BOWN Comparison

IVA vs BOWN Comparison

Compare IVA & BOWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVA
  • BOWN
  • Stock Information
  • Founded
  • IVA 2011
  • BOWN 2023
  • Country
  • IVA France
  • BOWN United States
  • Employees
  • IVA N/A
  • BOWN N/A
  • Industry
  • IVA Biotechnology: Pharmaceutical Preparations
  • BOWN
  • Sector
  • IVA Health Care
  • BOWN
  • Exchange
  • IVA Nasdaq
  • BOWN Nasdaq
  • Market Cap
  • IVA 117.3M
  • BOWN 100.3M
  • IPO Year
  • IVA 2020
  • BOWN 2023
  • Fundamental
  • Price
  • IVA $2.35
  • BOWN $10.92
  • Analyst Decision
  • IVA Strong Buy
  • BOWN
  • Analyst Count
  • IVA 4
  • BOWN 0
  • Target Price
  • IVA $13.25
  • BOWN N/A
  • AVG Volume (30 Days)
  • IVA 9.3K
  • BOWN 40.2K
  • Earning Date
  • IVA 09-25-2024
  • BOWN 01-01-0001
  • Dividend Yield
  • IVA N/A
  • BOWN N/A
  • EPS Growth
  • IVA N/A
  • BOWN N/A
  • EPS
  • IVA N/A
  • BOWN 0.39
  • Revenue
  • IVA $20,652,523.00
  • BOWN N/A
  • Revenue This Year
  • IVA N/A
  • BOWN N/A
  • Revenue Next Year
  • IVA $361.78
  • BOWN N/A
  • P/E Ratio
  • IVA N/A
  • BOWN $28.18
  • Revenue Growth
  • IVA N/A
  • BOWN N/A
  • 52 Week Low
  • IVA $1.53
  • BOWN $10.32
  • 52 Week High
  • IVA $4.75
  • BOWN $10.98
  • Technical
  • Relative Strength Index (RSI)
  • IVA 36.64
  • BOWN 53.13
  • Support Level
  • IVA $2.22
  • BOWN $10.93
  • Resistance Level
  • IVA $2.39
  • BOWN $10.97
  • Average True Range (ATR)
  • IVA 0.10
  • BOWN 0.02
  • MACD
  • IVA -0.03
  • BOWN -0.01
  • Stochastic Oscillator
  • IVA 24.76
  • BOWN 14.29

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

About BOWN Bowen Acquisition Corp

Bowen Acquisition Corp is a blank check company.

Share on Social Networks: